These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 19255335

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.
    Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
    [Abstract] [Full Text] [Related]

  • 3. [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].
    Couto Mdo R, Pinto D, Oliveira J, Monteiro A, Pereira D, Medeiros R, Rodrigues H.
    Acta Med Port; 2011; 24(1):5-16. PubMed ID: 21672436
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
    Goldenberg MM.
    Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
    [Abstract] [Full Text] [Related]

  • 11. Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer.
    Ardavanis A, Kountourakis P, Kyriakou F, Malliou S, Mantzaris I, Garoufali A, Yiotis I, Scorilas A, Baziotis N, Rigatos G.
    Oncologist; 2008 Apr; 13(4):361-9. PubMed ID: 18448549
    [Abstract] [Full Text] [Related]

  • 12. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility.
    Ghedini GC, Ciravolo V, Tortoreto M, Giuffrè S, Bianchi F, Campiglio M, Mortarino M, Figini M, Coliva A, Carcangiu ML, Zambetti M, Piazza T, Ferrini S, Ménard S, Tagliabue E, Pupa SM.
    J Cell Physiol; 2010 Oct; 225(1):256-65. PubMed ID: 20506359
    [Abstract] [Full Text] [Related]

  • 13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
    Dank M.
    Orv Hetil; 2001 Nov 18; 142(46):2563-8. PubMed ID: 11770175
    [Abstract] [Full Text] [Related]

  • 14. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M, Grell P, Simícková M, Fabian P, Petráková K, Palácová M, Macková D, Trojanec R, Hajdúch M, Pavlík T, Nenutil R, Vyzula R.
    Klin Onkol; 2008 Nov 18; 21(6):348-58. PubMed ID: 19382598
    [Abstract] [Full Text] [Related]

  • 15. Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer.
    Sorensen BS, Mortensen LS, Andersen J, Nexo E.
    Anticancer Res; 2010 Jun 18; 30(6):2463-8. PubMed ID: 20651409
    [Abstract] [Full Text] [Related]

  • 16. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
    Sandri MT, Johansson H, Colleoni M, Zorzino L, Passerini R, Orlando L, Viale G.
    Anticancer Res; 2004 Jun 18; 24(2C):1261-6. PubMed ID: 15154657
    [Abstract] [Full Text] [Related]

  • 17. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
    Nahta R, O'Regan RM.
    Clin Breast Cancer; 2010 Nov 18; 10 Suppl 3():S72-8. PubMed ID: 21115425
    [Abstract] [Full Text] [Related]

  • 18. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.
    Nishimura R, Okumura Y, Arima N.
    Breast Cancer; 2008 Nov 18; 15(1):57-64. PubMed ID: 18224396
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.